Fig 1.
Patient selection flow diagram.
Flow diagram depicting the exclusion of patients from the initial sequential cohort. CHF = Congestive heart failure, HIV = human immunodeficiency virus, CKD ≥ 4 = chronic kidney disease greater or equal to stage 4, transplant = patients who underwent any organ transplant, LR 4 = Liver Imaging Reporting and Data System LIRADS (LR)-4 (LR-4), LR-TR = LR treatment response, LRM = LR- likely malignant, and HCC/LR-5 lesions IBD = inflammatory bowel disease. Autoimmune disease was a category of a wide variety of autoimmune diseases including autoimmune hepatitis.
Fig 2.
Segmentation of paraspinous muscles to calculate SMI and sFF.
Segmentation of paraspinous musculature on in-phase (IP) (left) and out of phase (OOP) (right) paired MRI gradient echo (GRE) sequences at the level of the superior mesenteric artery origin.
Fig 3.
Regions of interest placement to calculate CEFR.
Region of interest placement within the bilateral paraspinous muscles and central aorta at the level of the superior mesenteric artery origin for calculation of paraspinous skeletal muscle contrast enhancement fraction (PSM CEFR). Measurements were obtained on non-contrast (NON-CON) (top left), arterial (ART) (top right), portal venous (PV) (bottom left), and delayed (DEL) (bottom right) phases.
Table 1.
Population characteristics.
Table 2.
Univariate analysis of Imaging biomarkers and their association with clinical measures of cirrhosis severity.
Table 3.
Correlations between imaging biomarkers and clinical and laboratory variables.